Georgia Konstantinidou

Bern, BE 3010, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion.

Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion.

Journal: Cell reports

Published: May 19, 2026

Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion.

Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion.

Journal: Cell reports

Published: May 19, 2025

ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer.

ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer.

Journal: EMBO molecular medicine

Published: November 02, 2023

An optimized protocol for the generation and monitoring of conditional orthotopic lung cancer in the KP mouse model using an adeno-associated virus vector compatible with biosafety level 1.

An optimized protocol for the generation and monitoring of conditional orthotopic lung cancer in the KP mouse model using an adeno-associated virus vector compatible with biosafety level 1.

Journal: Cancer immunology, immunotherapy : CII

Published: March 15, 2023

Lipid Metabolic Alterations in KRAS Mutant Tumors: Unmasking New Vulnerabilities for Cancer Therapy.

Lipid Metabolic Alterations in KRAS Mutant Tumors: Unmasking New Vulnerabilities for Cancer Therapy.

Journal: International journal of molecular sciences

Published: December 02, 2022

Restriction of extracellular lipids renders pancreatic cancer dependent on autophagy.

Restriction of extracellular lipids renders pancreatic cancer dependent on autophagy.

Journal: Journal of experimental & clinical cancer research : CR

Published: August 05, 2021

Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology.

Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology.

Journal: Cancers

Published: December 31, 2020

Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer.

Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer.

Journal: EMBO molecular medicine

Published: August 02, 2020

ACSL3-PAI-1 signaling axis mediates tumor-stroma cross-talk promoting pancreatic cancer progression.

ACSL3-PAI-1 signaling axis mediates tumor-stroma cross-talk promoting pancreatic cancer progression.

Journal: Science advances

Published: March 26, 2020

Editorial: Oncogenic RAS-Dependent Reprogramming of Cellular Plasticity.

Editorial: Oncogenic RAS-Dependent Reprogramming of Cellular Plasticity.

Journal: Frontiers in oncology

Published: February 24, 2020

The ACSL3-LPIAT1 signaling drives prostaglandin synthesis in non-small cell lung cancer.

The ACSL3-LPIAT1 signaling drives prostaglandin synthesis in non-small cell lung cancer.

Journal: Oncogene

Published: September 25, 2019

Targeting Long Chain Acyl-CoA Synthetases for Cancer Therapy.

Targeting Long Chain Acyl-CoA Synthetases for Cancer Therapy.

Journal: International journal of molecular sciences

Published: June 28, 2019

Showing 1-12 of 21

Last Updated: 09/26/2026